SCHEMBL2064243

SCHEMBL2064243

[CH2]CCCOc1cccc(Nc2ccnc(Cl)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 3/20 0.56
ROCK2 O75116 1/20 0.56
PRKACA P17612 1/20 0.56
PRKCD Q05655 1/20 0.56
DYRK1A Q13627 1/20 0.56
CDC42BPA Q5VT25 1/20 0.56
EGFR P00533 2/20 0.48
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
IGF1R P08069 4/20 0.40
SYK P43405 3/20 0.40
ERBB3 P21860 1/20 0.39
AIMP2 Q13155 1/20 0.39
MAP3K5 Q99683 1/20 0.38
AGER Q15109 1/20 0.38
KDR P35968 1/20 0.38
AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6969576 0.83 EGFR (0.54) ROCK1ROCK2PRKACAPRKCDDYRK1A
SCHEMBL6978657 0.80 EGFR (0.72) ROCK1EGFRIGF1RERBB3KDR
SCHEMBL655624 0.80 SYK (0.53) ROCK1ROCK2PRKACAPRKCDDYRK1A
SCHEMBL6980608 0.77 IGF1R (0.60) ROCK1ROCK2PRKACAPRKCDDYRK1A
SCHEMBL3211816 0.75 HTR3E (0.72) ROCK1PRKCDEGFRHTR3EHTR3B
SCHEMBL14447584 0.73 ROCK1 (0.60) ROCK1ROCK2PRKACAPRKCDDYRK1A
SCHEMBL13166085 0.73 NFKB1 (0.58) ROCK1ROCK2DYRK1ACDC42BPAEGFR
SCHEMBL657019 0.73 SYK (0.70) ROCK1ROCK2PRKACAPRKCDDYRK1A
SCHEMBL19089362 0.73 KDR (0.54) ROCK1EGFRHTR3EHTR3BHTR3A
SCHEMBL1027634 0.73 ROCK1 (0.52) ROCK1ROCK2PRKACAPRKCDDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1824856-B1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2013-10-23 EP disclosed
US-8148388-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-04-03 US disclosed
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-24 US disclosed
EP-1824856-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-29 EP disclosed
WO-2006061415-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR1H3, NR1H2, NR0B1 ROCK1 3492/4885ROCK2 3724/4885PRKACA 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.